Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) had its price objective dropped by research analysts at Deutsche Bank AG from $160.00 to $153.00 in a report issued on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank AG’s price objective points to a potential upside of 56.60% from the company’s current price.

A number of other equities analysts have also recently commented on the company. Nomura assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, March 1st. They set a “buy” rating for the company. BMO Capital Markets reissued an “outperform” rating and set a $158.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, May 1st. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a report on Tuesday. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Alexion Pharmaceuticals in a report on Thursday, February 16th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $157.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday. Seven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $164.49.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.81% during mid-day trading on Thursday, reaching $97.70. The company had a trading volume of 6,660,773 shares. The company has a market capitalization of $21.94 billion, a price-to-earnings ratio of 46.55 and a beta of 1.39. The stock has a 50 day moving average of $118.87 and a 200-day moving average of $123.96. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $157.02.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. The company had revenue of $870 million for the quarter, compared to the consensus estimate of $826.63 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. Alexion Pharmaceuticals’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.11 earnings per share. On average, analysts expect that Alexion Pharmaceuticals will post $5.32 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/05/27/alexion-pharmaceuticals-inc-alxn-price-target-lowered-to-153-00-at-deutsche-bank-ag.html.

In other news, SVP Edward Miller sold 260 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $131.20, for a total transaction of $34,112.00. Following the sale, the senior vice president now owns 15,214 shares in the company, valued at $1,996,076.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Leonard Bell sold 2,738 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $131.71, for a total value of $360,621.98. Following the sale, the director now owns 391,910 shares in the company, valued at approximately $51,618,466.10. The disclosure for this sale can be found here. Insiders have sold 11,476 shares of company stock worth $1,504,601 in the last quarter. Insiders own 4.41% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Hudson Bay Capital Management LP bought a new position in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $12,847,000. Honeywell International Inc. bought a new position in shares of Alexion Pharmaceuticals during the third quarter valued at about $21,567,000. Sumitomo Mitsui Asset Management Company LTD boosted its position in shares of Alexion Pharmaceuticals by 10.9% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 18,859 shares of the biopharmaceutical company’s stock valued at $2,286,000 after buying an additional 1,849 shares during the period. Janus Capital Management LLC boosted its position in shares of Alexion Pharmaceuticals by 7.6% in the fourth quarter. Janus Capital Management LLC now owns 919,413 shares of the biopharmaceutical company’s stock valued at $112,504,000 after buying an additional 65,266 shares during the period. Finally, Xact Kapitalforvaltning AB raised its stake in shares of Alexion Pharmaceuticals by 7.2% in the first quarter. Xact Kapitalforvaltning AB now owns 36,430 shares of the biopharmaceutical company’s stock worth $4,417,000 after buying an additional 2,434 shares in the last quarter. Hedge funds and other institutional investors own 94.98% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

12 Month Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.